CABA

Insider Trades

Name	Value	Action	Price	Current Price
Nichtberger StevenDirector, Officer: President & CEO $101k45k shares BuyJan 21, 2026 $2.24 --
Gavel SteveChief Commercial Officer $50k22.2k shares BuyJan 21, 2026 $2.27 --
Tomasello ShawnDirector $50k22.7k shares BuyJan 21, 2026 $2.21 --
Simon MarkDirector $25k11.1k shares BuyJan 21, 2026 $2.28 --
Binder GwendolynPresident, Science & Tech. $25k11.3k shares BuyJan 21, 2026 $2.19 --
Chang David J.Chief Medical Officer $20k8.8k shares BuyJan 21, 2026 $2.26 --

News

seekingalpha.comCabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 8

globenewswire.comCabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congressglobenewswire.comJun 3

zacks.comIs Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?zacks.comMay 20

zacks.comCabaletta Bio (CABA) Upgraded to Buy: Here's Whyzacks.comMay 18

seekingalpha.comCabaletta Bio Q1 Earnings: More Positive Data Suggests CAR-T Can Work In Autoimmuneseekingalpha.comMay 14

Trade CABA

About Cabaletta Bio, Inc.

Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also includes MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris. The company maintains strategic alliances, including a collaboration with the University of Pennsylvania and a research pact with The Regents of the University of California. Founded in 2017 as Tycho Therapeutics, Inc., it adopted the name Cabaletta Bio, Inc. in August 2018 and is based in Philadelphia, Pennsylvania.

CEO: Steven A. Nichtberger
IPO Date: Oct 25, 2019

Market Data

Open: $2.93
High: $2.96
Low: $2.83
Volume: 17.2M
Avg Volume: 3.7M
52W High: $4.23
52W Low: $1.26

Valuation

Market Cap: $463M
Enterprise Value: $373M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-132M
Revenue: $0
Net Income: $-168M
Cash: $83M
Debt: $27M

Events

EarningsAug 6

EPS est. -0.37